CN105061411A - Optical isomer 2S,4R,2'S-itraconazole crystal form, preparation method and applications thereof - Google Patents
Optical isomer 2S,4R,2'S-itraconazole crystal form, preparation method and applications thereof Download PDFInfo
- Publication number
- CN105061411A CN105061411A CN201510350844.3A CN201510350844A CN105061411A CN 105061411 A CN105061411 A CN 105061411A CN 201510350844 A CN201510350844 A CN 201510350844A CN 105061411 A CN105061411 A CN 105061411A
- Authority
- CN
- China
- Prior art keywords
- itraconazole
- optical isomer
- crystal formation
- preparation
- itraconazole crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004130 itraconazole Drugs 0.000 title claims abstract description 81
- 239000013078 crystal Substances 0.000 title claims abstract description 62
- 230000003287 optical effect Effects 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 230000000843 anti-fungal effect Effects 0.000 claims abstract description 6
- 206010017533 Fungal infection Diseases 0.000 claims abstract description 4
- 208000031888 Mycoses Diseases 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 41
- 238000002425 crystallisation Methods 0.000 claims description 14
- 230000008025 crystallization Effects 0.000 claims description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000002447 crystallographic data Methods 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 238000003828 vacuum filtration Methods 0.000 claims description 4
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 230000000384 rearing effect Effects 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 4
- 206010060862 Prostate cancer Diseases 0.000 abstract description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 2
- 229940124302 mTOR inhibitor Drugs 0.000 abstract description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 239000005030 aluminium foil Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- -1 alkyl itraconazole Chemical compound 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000004862 dioxolanes Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention discloses an optical isomer 2S,4R,2'S-itraconazole crystal form, a preparation method and applications thereof. According to the present invention, the optical isomer 2S,4R,2'S-itraconazole crystal form has characteristics of high stability, high purity and good drug activity; the preparation method has characteristics of simpleness and low cost, and is easily subjected to large-scale and industrial production; and the optical isomer 2S,4R,2'S-itraconazole crystal form and the pharmaceutical composition containing the crystal form can be used for anti-fungal infection, and are the effective mTOR inhibitors so as to can be used for treatments of a variety of tumors (such as non-small-cell lung cancer, prostate cancer, and the like).
Description
Technical field
The present invention relates to optical isomer 2S, 4R, 2 ' S-itraconazole, especially relates to optical isomer 2S, 4R, 2 ' S-itraconazole crystal formation and preparation method and application.
Background technology
Itraconazole is a kind of triazole species broad-spectrum antifungal medicine, its English name is Itraconazole, the cis-4-of chinesization formal name used at school [4-[4-[4-[[-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-yl methyl)-DOX-4-base] methoxyl group] phenyl] piperazine-1-base] phenyl]-2-[(2 ' S)-1-methyl-propyl]-1,2,4-triazole-3-ketone.Itraconazole has 3 chiral carbon atoms, have 8 kinds of optical isomers, antimycotic Clinical practice be the mixture of 4 cis-isomerides on dioxolanes in its structure, correspond to 2S, 4R, 2 ' S-itraconazole, 2S, 4R, 2 ' R-itraconazole, 2R, 4S, 2 ' S-itraconazole and 2R, 4S, 2 ' R-itraconazole.
In the recent period, document ChemBiol, 2007 (2): 263-70 report itraconazole has potential suppression vascular endothelial proliferation effect, and other antifungal drugs as fluconazole, KETOKONAZOL etc. on vascular endothelial cell without impact; CN101711156A discloses a kind of method of itraconazole single chiral pure isomer prevention and therapy relevant diseases of angiogenesis, and itraconazole isomer can Tumor suppression new vessel, is antineoplastic candidate compound.
The itraconazole serious adverse reaction clinically of racemization comprises gastrointestinal discomfort, as apocleisis, feel sick, stomachache and constipation, rare side effect comprises headache, the rising of reversibility transaminase, menoxenia, dizziness and anaphylaxis (as itch, erythema, wheal and angioedema), especially liver toxicity, a general course for the treatment of is two weeks, to the damage of liver clearly, can be there is liver failure and cause death in severe patient, over the course for the treatment of usually not by as a line medication.Document DRUGMETABOLISMANDDISPOSITION.2006, human body metabolism's result of study that 34:583-590. reports itraconazole four cis-isomerides shows, only has 2R, 4S, 2 ' R and 2R, 4S, 2 ' S can be metabolized to R 63373 by CYP3A4, ketone group itraconazole and N-take off alkyl itraconazole, and 2S, 4R, 2 ' R and 2S, 4R, 2 ' S can not by metabolism, thus there is higher bioavailability, hepatotoxicity experiment test also shows, itraconazole isomer 2S, 4R, 2 ' S and 2R, 4S, 2 ' S has higher security, therefore, preparation individual isomer 2S, 4R, the stable crystalline of 2 ' S-itraconazole, for the physicochemical property studying this compound further, study its drug regimen and clinical application, tool is of great significance.
Summary of the invention
The object of the invention is the deficiency existed for prior art, provide a kind of new optical isomer 2S, 4R, 2 ' S-itraconazole crystal formation, has good stability, has good pharmaceutical activity.
For achieving the above object, the technical solution used in the present invention is:
A kind of optical isomer 2S, 4R, 2 ' S-itraconazole crystal formation, described optical isomer 2S, 4R, 2 ' S-itraconazole crystal form X diffraction data is as shown in the table:
Represent apart from d with crystal face,
with
there is diffraction peak at place.Optical isomer 2S, 4R, the X-ray diffractogram of 2 ' S-itraconazole crystal formation as shown in Figure 1.
Its DSC collection of illustrative plates, has endotherm(ic)peak at 162.3 DEG C.Optical isomer 2S, 4R, the DSC collection of illustrative plates of 2 ' S-itraconazole crystal formation as shown in Figure 2.
Its melting range is 162.5 DEG C ~ 162.9 DEG C.
Present invention also offers a kind of described optical isomer 2S, 4R, the preparation method of 2 ' S-itraconazole crystal formation, comprises the steps:
(1) by 2S, 4R, 2 ' S-itraconazole is dissolved in 40 ~ 100 DEG C of organic solvents, and described organic solvent is propyl carbinol, Virahol, ethyl acetate, methylene dichloride, toluene, acetonitrile, acetone, DMF, tetrahydrofuran (THF) or their mixed solvent;
(2) limit is stirred, and limit lowers the temperature, and be cooled to 35 ~ 55 DEG C, crystallize out, continue to be cooled to 0 ~ 25 DEG C, insulated and stirred growing the grain is complete to crystallization;
(3) vacuum filtration or centrifugation, collect crystal, air blast or vacuum-drying, obtain 2S, 4R, 2 ' S-itraconazole crystallization.
In step (1), the mass volume ratio of solute and solvent is 1:5 ~ 1:40.
In step (2), cooling extent is per minute 1 DEG C ~ 10 DEG C, and growing the grain temperature is 0 ~ 25 DEG C, and rearing crystal time is 0.5 ~ 10h.
In step (3), drying temperature is 30 DEG C ~ 90 DEG C.
Present invention also offers a kind of described optical isomer 2S, 4R, 2 ' S-itraconazole crystal formation is for the preparation of the application in anti-fungal infection and tumor.
Present invention also offers pharmaceutical composition, comprise described a kind of optical isomer 2S, 4R, 2 ' S-itraconazole crystal formation.
The present invention compared with prior art, has the following advantages:
Optical isomer 2S, 4R of the present invention, 2 ' S-itraconazole crystal formation crystal is single, and purity is higher, and stability is better, and solubleness is higher, has good pharmaceutical activity and higher bioavailability.Preparation method of the present invention is simple, and cost is lower, easily realizes mass-producing, suitability for industrialized production.Described optical isomer 2S, 4R, 2 ' S-itraconazole crystal formation, and the pharmaceutical composition containing this crystal formation, not only can be used for anti-fungal infection, or a kind of effective mTOR inhibitors, therefore also can be used for the treatment of various tumour (as nonsmall-cell lung cancer, prostate cancer etc.).
Accompanying drawing explanation
Fig. 1 is optical isomer 2S, 4R, the X-ray diffractogram of 2 ' S-itraconazole crystal formation.
Fig. 2 is optical isomer 2S, 4R, the DSC collection of illustrative plates of 2 ' S-itraconazole crystal formation.
Embodiment
Below in conjunction with the drawings and specific embodiments, illustrate the present invention further, these embodiments should be understood only be not used in for illustration of the present invention and limit the scope of the invention, after having read the present invention, the amendment of those skilled in the art to the various equivalent form of value of the present invention has all fallen within the application's claims limited range.
The invention discloses a kind of optical isomer 2S, 4R, 2 ' S-itraconazole crystal formation, has X-ray diffraction spectrogram as represented in figure 1.Those skilled in the art are to be understood that; optical isomer 2S of the present invention; 4R; 2 ' S-itraconazole crystal formation is not limited only to the diffraction peak occurred at above-mentioned 2 θ angle places; also should comprise due to be subject to impact as factors such as experimental errors and above-mentioned 2 θ angles ± 0.02 ° in the diffraction peak that occurs, should also in protection scope of the present invention.
As shown in Figure 1, a kind of optical isomer 2S, 4R, 2 ' S-itraconazole crystal formation, described optical isomer 2S, 4R, 2 ' S-itraconazole crystal form X diffraction data is as shown in the table:
Table 12S, 4R, the X diffraction data of 2 ' S-itraconazole crystallization
, represent apart from d with crystal face,
with
there is diffraction peak at place.Represent apart from d with crystal face, about
with
there is one or more characteristic diffraction peak at place.
As shown in Figure 2, optical isomer 2S, 4R, the DSC collection of illustrative plates of 2 ' S-itraconazole crystal formation, has endotherm(ic)peak at 162.3 DEG C, and its melting range is 162.5 DEG C ~ 162.9 DEG C.
Present invention also offers a kind of described optical isomer 2S, 4R, the preparation method of 2 ' S-itraconazole crystal formation, comprises the steps:
(1) by 2S, 4R, 2 ' S-itraconazole is dissolved in 40 ~ 100 DEG C of organic solvents, and described organic solvent is propyl carbinol, Virahol, ethyl acetate, methylene dichloride, toluene, acetonitrile, acetone, DMF, tetrahydrofuran (THF) or their mixed solvent;
(2) limit is stirred, and limit lowers the temperature, and be cooled to 35 ~ 55 DEG C, crystallize out, continue to be cooled to 0 ~ 25 DEG C, insulated and stirred growing the grain is complete to crystallization;
(3) vacuum filtration or centrifugation, collect crystal, air blast or vacuum-drying, obtain 2S, 4R, 2 ' S-itraconazole crystallization.
In step (1), the mass volume ratio of solute and solvent is 1:5 ~ 1:40.
In step (2), cooling extent is per minute 1 DEG C ~ 10 DEG C, and growing the grain temperature is 0 ~ 25 DEG C, and rearing crystal time is 0.5 ~ 10h.
In step (3), drying temperature is 30 DEG C ~ 90 DEG C.
Optical isomer 2S, 4R of the present invention, 2 ' S-itraconazole crystal formation is for the preparation of the active substance crystallization in medical composition, there is high purity and high stability, even if under harsher condition of storage, also can keep stable, can not change in preparation preparation subsequently and storage.
Embodiment 1: optical isomer 2S, 4R, the preparation of 2 ' S-itraconazole crystal formation
Get optical isomer 2S, 4R, 2 ' S-itraconazole 15g, in reaction flask, adds 600ml Virahol, reflux, stirs clearly molten, and limit is stirred, while be cooled to 0 DEG C, separates out solid, continues cooling and stirs 10h.Vacuum filtration, filter cake, in 90 DEG C of forced air drying 12h, obtains 12.8g white needles, yield 85.3%.
Embodiment 2: optical isomer 2S, 4R, the preparation of 2 ' S-itraconazole crystal formation
Get optical isomer 2S, 4R, 2 ' S-itraconazole 10g, in reaction flask, adds 50ml methylene dichloride, reflux, stirs clearly molten, be cooled to 0 DEG C, separates out solid, and continue insulated and stirred 5h, crystallization is complete.Suction filtration, filter cake, in 30 DEG C of vacuum-drying 12h, obtains 4.4g white needles, yield 44%.
Embodiment 3: optical isomer 2S, 4R, the preparation of 2 ' S-itraconazole crystal formation
Get 2S, 4R, 2 ' S-itraconazole 1kg, in reaction flask, adds 30L methylene dichloride, reflux, stirs clearly molten, be cooled to 25 DEG C, separates out solid, and continue insulated and stirred 0.5h, crystallization is complete.Centrifugation, obtains solid, and forced air drying 8h at 50 DEG C, obtains 870g white needles, yield 87%.
Embodiment 4: optical isomer 2S, 4R, the illumination experiment of 2 ' S-itraconazole crystal formation
Optical isomer 2S embodiment 3 provided, 4R, 2 ' S-itraconazole crystal formation is evenly shared in uncovered culture dish respectively, thickness≤5mm, and regulating illumination intensity is 4500 ± 500Lx, samples detection after 30 days, and contrasts in the result of 0 day.The results are shown in Table 2.
Table 22S, 4R, the illumination experiment of 2 ' S-itraconazole crystallization
Embodiment 5: optical isomer 2S, 4R, the high temperature experiment of 2 ' S-itraconazole crystal formation
The optical isomer 2S embodiment of the present invention 3 provided, 4R, 2 ' S-itraconazole crystal formation is positioned in sealing aluminium foil bag, is placed in 60 DEG C of thermostatic drying chambers, detects after 30 days, and contrast in the result of 0 day.The results are shown in Table 2.
Table 32S, 4R, 2 ' S-itraconazole crystallization high temperature experiment
Embodiment 6: optical isomer 2S, 4R, the Acceleration study of 2 ' S-itraconazole crystal formation
By the 2S provided of the embodiment of the present invention 3,4R, 2 ' S-itraconazole crystal is positioned in aluminium foil bag respectively, is placed in 40 ± 2 DEG C, and relative humidity is in the thermostatic drying chamber of 75 ± 5%, detects after 30 days, and contrasts in the result of 0 day.The results are shown in Table 4.
Table 42S, 4R, 2 ' S-itraconazole crystallization Acceleration study
Embodiment 7: optical isomer 2S, 4R, the pharmaceutical activity test of 2 ' S-itraconazole crystal formation
By the 2S provided of the embodiment of the present invention 3,4R, 2 ' S-itraconazole crystal formation and itraconazole are hatched with HUVEC cell and human primary hepatocyte respectively, obtain two kinds of medicines to the restraining effect of cytoactive.As shown in the table.
Table 52S, 4R, 2 ' S-itraconazole crystallization
From result of study, by the 2S provided of the embodiment of the present invention 3,4R, the restraining effect of 2 ' S-itraconazole crystal formation to Human umbilical vein endothelial cells (HUVEC) is better than raceme itraconazole, and to the suppression of human primary hepatocyte lower than raceme itraconazole, 2S is described, 4R, 2 ' S-itraconazole crystal has higher anti-tumor activity and lower liver toxicity.
Claims (10)
1. an optical isomer 2S, 4R, 2 ' S-itraconazole crystal formation, is characterized in that, described optical isomer 2S, 4R, and 2 ' S-itraconazole crystal form X diffraction data is as shown in the table:
2. optical isomer 2S, 4R according to claim 1,2 ' S-itraconazole crystal formation, is characterized in that: represent apart from d with crystal face,
with
there is diffraction peak at place.
3. optical isomer 2S, 4R according to claim 1,2 ' S-itraconazole crystal formation, is characterized in that: its DSC collection of illustrative plates, has endotherm(ic)peak at 162.3 DEG C.
4. optical isomer 2S, 4R according to claim 1,2 ' S-itraconazole crystal formation, is characterized in that: its melting range is 162.5 DEG C ~ 162.9 DEG C.
5. any one optical isomer 2S described in Claims 1-4,4R, the preparation method of 2 ' S-itraconazole crystal formation, is characterized in that, comprise the steps:
(1) by 2S, 4R, 2 ' S-itraconazole is dissolved in 40 ~ 100 DEG C of organic solvents, and described organic solvent is propyl carbinol, Virahol, ethyl acetate, methylene dichloride, toluene, acetonitrile, acetone, DMF, tetrahydrofuran (THF) or their mixed solvent;
(2) limit is stirred, and limit lowers the temperature, and be cooled to 35 ~ 55 DEG C, crystallize out, continue to be cooled to 0 ~ 25 DEG C, insulated and stirred growing the grain is complete to crystallization;
(3) vacuum filtration or centrifugation, collect crystal, air blast or vacuum-drying, obtain 2S, 4R, 2 ' S-itraconazole crystallization.
6. optical isomer 2S, 4R according to claim 5, the preparation method of 2 ' S-itraconazole crystal formation, is characterized in that: in step (1), and the mass volume ratio of solute and solvent is 1:5 ~ 1:40.
7. optical isomer 2S, 4R according to claim 5, the preparation method of 2 ' S-itraconazole crystal formation, is characterized in that: in step (2), and cooling extent is per minute 1 DEG C ~ 10 DEG C, and growing the grain temperature is 0 ~ 25 DEG C, and rearing crystal time is 0.5 ~ 10h.
8. optical isomer 2S, 4R according to claim 5, the preparation method of 2 ' S-itraconazole crystal formation, is characterized in that: in step (3), and drying temperature is 30 DEG C ~ 90 DEG C.
9. any one optical isomer 2S described in Claims 1-4,4R, 2 ' S-itraconazole crystal formation is for the preparation of the application in anti-fungal infection and tumor.
10. a pharmaceutical composition, is characterized in that: comprise any one optical isomer 2S described in Claims 1-4,4R, 2 ' S-itraconazole crystal formation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510350844.3A CN105061411A (en) | 2015-06-23 | 2015-06-23 | Optical isomer 2S,4R,2'S-itraconazole crystal form, preparation method and applications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510350844.3A CN105061411A (en) | 2015-06-23 | 2015-06-23 | Optical isomer 2S,4R,2'S-itraconazole crystal form, preparation method and applications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105061411A true CN105061411A (en) | 2015-11-18 |
Family
ID=54490975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510350844.3A Pending CN105061411A (en) | 2015-06-23 | 2015-06-23 | Optical isomer 2S,4R,2'S-itraconazole crystal form, preparation method and applications thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105061411A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106478615A (en) * | 2016-08-31 | 2017-03-08 | 山东罗欣药业集团股份有限公司 | A kind of Itraconazole crystal-form compound and preparation method thereof |
| CN111603470A (en) * | 2020-07-01 | 2020-09-01 | 江苏艾迪药业股份有限公司 | Application of itraconazole isomer in preparation of drugs for treating squamous non-small cell lung cancer |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993019061A1 (en) * | 1992-03-18 | 1993-09-30 | Janssen Pharmaceutica N.V. | Itraconazole and saperconazole stereoisomers |
| CN103191119A (en) * | 2013-04-03 | 2013-07-10 | 南京安赛莱医药科技有限公司 | Use of itraconazole in inhibiting of Akt kinase (protein kinase B) activity |
| CN104774195A (en) * | 2015-03-10 | 2015-07-15 | 扬州艾迪生物科技有限公司 | Optically pure itraconazole key intermediate, synthetic method thereof, and method for synthesizing optically pure itraconazole from the intermediate |
| CN104788437A (en) * | 2015-04-14 | 2015-07-22 | 扬州艾迪生物科技有限公司 | Method for chiral resolution of itraconazole |
-
2015
- 2015-06-23 CN CN201510350844.3A patent/CN105061411A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993019061A1 (en) * | 1992-03-18 | 1993-09-30 | Janssen Pharmaceutica N.V. | Itraconazole and saperconazole stereoisomers |
| CN103191119A (en) * | 2013-04-03 | 2013-07-10 | 南京安赛莱医药科技有限公司 | Use of itraconazole in inhibiting of Akt kinase (protein kinase B) activity |
| CN104774195A (en) * | 2015-03-10 | 2015-07-15 | 扬州艾迪生物科技有限公司 | Optically pure itraconazole key intermediate, synthetic method thereof, and method for synthesizing optically pure itraconazole from the intermediate |
| CN104788437A (en) * | 2015-04-14 | 2015-07-22 | 扬州艾迪生物科技有限公司 | Method for chiral resolution of itraconazole |
Non-Patent Citations (1)
| Title |
|---|
| WEI SHI，ET AL.: ""Impact of Absolute Stereochemistry on the Antiangiogenic and Antifungal Activities of Itraconazole"", 《ACS MED. CHEM. LETT.》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106478615A (en) * | 2016-08-31 | 2017-03-08 | 山东罗欣药业集团股份有限公司 | A kind of Itraconazole crystal-form compound and preparation method thereof |
| CN106478615B (en) * | 2016-08-31 | 2019-08-13 | 山东罗欣药业集团股份有限公司 | A kind of Itraconazole crystal-form compound and preparation method thereof |
| CN111603470A (en) * | 2020-07-01 | 2020-09-01 | 江苏艾迪药业股份有限公司 | Application of itraconazole isomer in preparation of drugs for treating squamous non-small cell lung cancer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101470715B1 (en) | Polymorphs of Dasatinib, preparation methods and pharmaceutical compositions thereof | |
| US12116356B2 (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | |
| US8530452B2 (en) | Tricyclic boron compounds for antimicrobial therapy | |
| KR20200039846A (en) | Novel crystal of uracil compound | |
| EP3269719A1 (en) | Crystal form of jak inhibitor and preparation method thereof | |
| US10882825B2 (en) | Non-solvated crystal, preparation method and application thereof | |
| US20250051334A1 (en) | Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use | |
| CN106565686A (en) | Tubulin inhibitor | |
| US20200062750A1 (en) | Crystalline Forms of Valbenazine Salts | |
| US8541391B2 (en) | Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole | |
| US9150600B2 (en) | Triptolide prodrugs | |
| CN105061411A (en) | Optical isomer 2S,4R,2'S-itraconazole crystal form, preparation method and applications thereof | |
| US20220315576A1 (en) | Polymorph of cdk9 inhibitor and preparation method for polymorph and use thereof | |
| ES2660642T3 (en) | Crystalline forms of dihydropyrimidine derivatives | |
| US20110269838A1 (en) | Novel processes and pure polymorphs | |
| CA2656711A1 (en) | Novel hydrate form of moxifloxacin monohydrochloride | |
| US10221185B2 (en) | Crystal form of substituted aminopyran derivativek | |
| EP3712136A1 (en) | Tebuconazole polymorph and preparation method therefor | |
| AU2015341341A1 (en) | Crystal forms of verapamil hydrochloride | |
| CN105992769A (en) | L-proline compound of sodium-glucose cotransporter 2 inhibitor, and monohydrate and crystal of l-proline compound | |
| CN109963855A (en) | A kind of crystal form and preparation method of BTK kinase inhibitor | |
| US20250122237A1 (en) | POLYMORPHIC SUBSTANCE OF A-DECARBURIZATION-5alpha ANDROSTANE COMPOUND | |
| US9758490B2 (en) | Antifungal compounds of (arylalkyl) azole derivatives in the structure of oxime ester | |
| CN103781774A (en) | New crystalline form | |
| CN110041368B (en) | Organic phosphine clinafloxacin derivative and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 225008 Liu Zhuang Road, Hanjiang District, Yangzhou, Jiangsu Province, No. 2 Applicant after: Jiangsu Aidi Pharmaceutical Co.,Ltd. Applicant after: NANJING ANSAILAI MEDICAL SCIENCE & TECHNOLOGY Co.,Ltd. Address before: 225008 Liu Zhuang Road, Hanjiang District, Yangzhou, Jiangsu Province, No. 2 Applicant before: JIANGSU AIDEA PHARMACEUTICAL CO.,LTD. Applicant before: NANJING ANSAILAI MEDICAL SCIENCE & TECHNOLOGY Co.,Ltd. Address after: 225008 Liu Zhuang Road, Hanjiang District, Yangzhou, Jiangsu Province, No. 2 Applicant after: JIANGSU AIDEA PHARMACEUTICAL CO.,LTD. Applicant after: NANJING ANSAILAI MEDICAL SCIENCE & TECHNOLOGY Co.,Ltd. Address before: 225008 VIP Road No. 2, Weiyang Economic Development Zone, Hanjiang District, Yangzhou, Jiangsu Applicant before: YANGZHOU AIDEA BIOTECH Co.,Ltd. Applicant before: NANJING ANSAILAI MEDICAL SCIENCE & TECHNOLOGY Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151118 |
|
| RJ01 | Rejection of invention patent application after publication |